<DOC>
	<DOCNO>NCT00485303</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety abiraterone acetate participant advanced prostate cancer ( disease cell prostate gland become abnormal start grow uncontrollably , form tumor ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Abiraterone Acetate Prednisone Participants With Prostate Cancer Who Failed Androgen Deprivation Docetaxel-Based Chemotherapy</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-arm , multicenter ( one hospital medical school team work medical research study ) study evaluate anti-tumor activity safety abiraterone acetate participant prostate cancer fail androgen deprivation docetaxel-based chemotherapy . Abiraterone acetate oral tablet administer total dose 1000 milligram ( mg ) orally ( mouth ) daily overnight fast prednisone/prednisolone administer 5 mg oral tablet twice daily . Participants enrol treat 12 cycle ( long , progress continue benefit treatment ) . The study consist 3 part : Screening ( 14 day ) , Open-label Treatment ; follow-up ( 60 month ) . Participants evaluate primarily prostate specific antigen response accord Prostate Specific Antigen Working Group ( PSAWG ) criterion . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma ( malignant epithelial tumor glandular organization ) prostate ( gland male reproductive system find bladder front rectum ) , neuroendocrine ( specialized neuron produce hormone , neuropeptides biogenic amine ) differentiation small cell histology Prior chemotherapy ( treatment disease , usually cancer , chemical agent ) prostate cancer regimen ( ) contain docetaxel Documented prostate specific antigen ( PSA ) progression accord Prostate Specific Antigen Working Group ( PSAWG ) eligibility criterion PSA ( &gt; ) 5 nanogram per milliliter ( ng/mL ) objective progression Response Evaluation Criteria Solid Tumors ( RESIST ) criteria Ongoing androgen deprivation serum testosterone le ( &lt; ) 50 nanogram per deciliter ( ng/dL ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status less equal ( &lt; = ) 2 ( Karnofsky Performance Status &gt; = 50 percent ) Active uncontrolled autoimmune disease ( disorder person 's immune system attack part body ) may require corticosteroid therapy Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Uncontrolled hypertension ( high blood pressure ) Hemoglobin &lt; =9.0 gram per deciliter ( g/dL ) without growth factor transfusion support Abnormal liver ( large organ help many body function , include digestion , metabolism , storage substance ) function</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>CB7630</keyword>
	<keyword>Prednisone</keyword>
</DOC>